A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...

The Food and Drug Administration has approved a new drug that could prevent HIV infections with just two shots every year and ...

Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

The initiative, referred to as the Commissioner's National Priority Voucher program, allows drug developers to participate in ...

WASHINGTON (AP) — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, maker Gilead Sciences announced ...

A federal judge has rejected a bid by compounding pharmacies to allow them to continue making copies of Novo Nordisk's ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

Gilead’s Yeztugo will offer an alternative to treatments such as daily pills and every-other-month injections.

But the Trump administration’s cuts to HIV programs in the U.S. and abroad could undermine the drug’s rollout.

Welcome to the latest edition of Investigative Roundup, highlighting some of the best investigative reporting on healthcare ...

The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.

The Food and Drug Administration says it will begin offering faster reviews to new medicines that align with Trump ...